Humanity has been struggling, yet a universal coronavirus vaccine designed by artificial intelligence (AI) has achieved success in human trials. This development is being hailed as a groundbreaking milestone in the era of artificial intelligence. NDTV Online reported the news, following an earlier report by the daily Manab Zamin. The latest report highlights that this vaccine was designed entirely using AI and has successfully completed its first clinical trial on humans. According to peer-reviewed data published in the Journal of Infection, 39 healthy adults aged 18 to 50 participated in this Phase-1 clinical trial.
The results demonstrated a 100% success rate regarding the vaccine’s safety profile; no serious side effects were observed. The vaccine was developed by the University of Cambridge in the UK and its spin-out company, DIOSynVax. Researchers claim it is capable of eliciting a robust immune response against various types of coronaviruses. This advancement heralds a significant shift: instead of repeatedly updating vaccines to match specific viral variants, this offers a single vaccine capable of potentially establishing universal protection.
The active component of this vaccine was designed entirely through computer simulations and machine learning algorithms. It is described as the first technology-driven vaccine of its kind to undergo human testing. Conventional vaccines typically train the immune system using specific parts of the virus, such as the spike protein. However, a challenge arises when the virus mutates rapidly, altering these target sites and thereby reducing vaccine efficacy. To address this, Cambridge researchers used AI models to analyze the genetic data of thousands of coronaviruses, including the COVID-19 virus, the 2003 SARS virus, and various animal-derived coronavirus strains. The AI system identified stable and immutable genetic characteristics shared among these viruses. Subsequently, these common structural elements are combined to create a master blueprint, which researchers have termed an “AI super-antigen.”
This strategy trains the body to produce antibodies that target the virus’s core structure. Consequently, it is believed that protection can be maintained even if external mutations occur. Participants in this trial did not receive injections via conventional syringes; instead, a specialized DNA vaccine delivery system utilizing microfluidic jet technology was employed. This technology delivers the vaccine into the skin using a high-pressure, minute stream of liquid. This method eliminates injection pain, alleviates needle phobia, and reduces both medical waste and risks associated with needles.
